"Chicom Among Us": Md GOP Lawmakers Sound Alarm On Chinese-Born Delegate's AI Disclosure Bill

 Rooting out Chinese communist spies appears to be moving higher on the agenda at the U.S. Justice Department, with Acting Attorney General Todd Blanche now at the helm.

On Monday, the DoJ indicted Arcadia, California, Mayor Eileen Wang for working with the Chinese government. The larger concern is that Chinese communists have penetrated deeply into many levels of the U.S. government, as well as corporate America.

Spies are like cockroaches: if there's one, there are likely many more.

That brings us to a recent podcast appearance by Mark Fisher and Brian Chisholm, Republican members of the Maryland House of Delegates, who raised alarm bells about one of their Democratic colleagues in Annapolis: Delegate Chao Wu, who was born in China and has pushed a state-level bill that would require AI companies to disclose sensitive trade data on their models.

"Welcome back to the Dumbest Bill in America. We have, of course, with us Delegate Brian Chisholm," Fisher said.

Fisher continued, "Because we believe that we have a communist Chicom among us. Well, and let me tell you why..." 

He said, "First of all, the bill is House Bill 823 from 2025. It was introduced by Delegate Wu — spelled W-U. And the bill basically says that if you're going to engage in AI training — artificial intelligence training — you have to disclose your training models and your training data every time you change it. Well, that would of course be a trade secret, wouldn't it?" 

Chisholm chimed in, saying, "So what their goal also in China… Look, China knows they can't take us down with tanks and bullets and all that. They have to kind of backdoor it. So they send in spies — people like Chao Wu — and try to gain intelligence, correct?" 

He continued, "That's the goal. The fight right now is who can get the intelligence faster. Why they sent us… it says something about Maryland. Maybe we're like the JV team that they sent Chao Wu to, because he's not the greatest of spies. I mean, his trail… and I'm sure you're going to bring up the article. We know he was working for the CCP when he was in college. You can't just reject it at one time…"

The article Chisholm was referring to...

Of course, Maryland Democrats call anything optically displeasing "racist" ...

Meanwhile, Dems in the state are "busy sending private letters policing podcasts and using CCP-style speech tactics." 

To sum up, HB 823 could compel AI developers in the state to publicly disclose commercially sensitive details about their training model pipelines, creating an opportunity for foreign competitors, such as China, to collect open-source data. 

Now, why would a Chinese-born Maryland lawmaker, right down the street from Data Center Alley, want to push such a bill?

https://www.zerohedge.com/political/communist-chicom-among-us-maryland-gop-lawmakers-sound-alarm-over-chinese-born-delegates

Cal. hopeful Becerra orders reporter to do puff piece on him; KTLA responds by releasing video of it

 by Monica Showalter

When's a reporter not a reporter, just a public relations adjunct of an incompetent, scandal-ridden, Democrat?

When Xavier Becerra, Democrat frontrunner in the California gubernatorial race by default after Eric Swalwell's embarrassing exit, is around.

Get a load of this disgusting exchange, attempting to intimidate a KTLA reporter into producing a puff piece about him:

Awkward moment kicks off KTLA interview with Xavier Becerra. @CaliforniaICP Full report: https://t.co/UcMXzidzrf pic.twitter.com/OViYkfTg3t

— KTLA (@KTLA) May 12, 2026

He's trying to come off as a mafia boss, which isn't inconsistent with what insiders have said about him, yet he's also quite the smug, self-satisfied, twerpy little jerk, trying to scare the very calm, professional, KTLA reporter into writing a flattering 'profile' as he calls it, about him. What he meant, of course, was puff piece.

Here's the Grok transcript, telling the reporter how to do her job:

Reporter: "With Xavier Becerra in Highland Park."

Becerra: "By the way, this is a profile piece, this is not a gotcha piece, right?"

Interviewer: "Well, look, I think these questions are fair. It's in order to learn about you as a candidate.

 

Becerra: "So long as it's about the profile."

Interviewer: "I don't know how you define it, but I'd like to begin the interview."

Becerra: "The way I describe a profile is you talk about all the things that I've done, things I want to do, and along with some tough questions. But not only tough questions."

Notice the ease with which he issues his instructions, as if he's been doing that for a long, long, time out in Sacramento and the Washington swamp, during his long, long career as a California attorney general, a congressman and a Health and Human Services secretary the great migrant surgee of Joe Biden, where he 'lost' 85,000 unaccompanied children brought into the U.S. as illegals, mismanaged the COVID response, and ran a waste-and-fraud-filled department full of empty buildings. He's telling the reporter how he wants her to write her story about him because that's what he always does, everyone else up until KTLA served as an obedient lapdog. 

The news station, which is one of Los Angeles's biggest and most influential and definitely not part of those two scenes, was apparently so disgusted by his jackass behavior it must have realized that it had news on its hands, and being newsmen, reported the news to the public as rather useful to the public in assessing this candidate's worth.

I've seen Becerra before, in action, over the years as a member of the press, and know that this wasn't an off day for him, this was him as he always is.

Is a candidate who insists on strictly puff piece coverage, the same way Kim Jong Il does, really the guy who plans to govern California well?

Or does he have a few things he's going to want to hide?

An outtake like this can only serve to alert voters to how wretched, arrogant, and incompetent he is. This is as good an argument against early voting as any out there, because voters need to see Becerra as he really is before they cast their ballots. KTLA has done a public service in releasing this video.

https://www.americanthinker.com/blog/2026/05/california_gubernatorial_candidate_xavier_becerra_orders_ktla_reporter_to_do_a_puff_piece_on_him_station_responds_by_releasing_video_of_it.html

Pharvaris maps trial roadmap, cash runway into 2028

 

Pharvaris reports Q1 2026 results with non-GAAP EPS $-0.69 (+27% YoY) and revenue $0, beats estimates, ends quarter with €247M cash and runway into 2028

• Cash runway into 2028 follows $132 million equity raise completed before March 31.
• Company plans NDA filing for deucrictibant IR in 1H 2026, reaffirming prior regulatory timeline.
• Pivotal CHAPTER-3 data for deucrictibant IR expected in 3Q 2026, in line with previous guidance.

https://finviz.com/quote?t=PHVS&p=d

NeuroPace beats, ups guidance

 

NeuroPace beats Q1 2026 EPS and revenue estimates and raises 2026 revenue guidance to $99–$101 million

• Fiscal Q1 2026 non-GAAP EPS was $-0.20, improving 5% year over year.
• Q1 2026 revenue was $22.0M, a 2% decline compared with the prior-year period.
• GAAP net loss for Q1 2026 was $0.20 per share.

https://finviz.com/quote?t=NPCE&p=d

Nvidia's Jensen Huang seen boarding Air Force One in Alaska

 Nvidia's Jensen Huang seen boarding Air Force One in Alaska - witness

https://www.marketscreener.com/news/nvidia-s-jensen-huang-seen-boarding-air-force-one-in-alaska-witness-ce7f5bdfda81f327

Steris misses, reaffirms guidance, eyes $1B buyback

 

STERIS reports fiscal Q4 2026 EPS $2.83 (+3% YoY) on revenue $1.6B (+7% YoY), both missing estimates

• Fiscal 2026 revenue rose 9% to $5.9B, according to the company’s full-year financial results.
• STERIS launched a new $1B share repurchase program alongside its fiscal 2026 results announcement.
• Fiscal 2027 guidance calls for 7–8% revenue growth compared with the prior fiscal year period.
• Fiscal 2027 adjusted EPS guidance is $11.10–$11.30, as outlined alongside the fiscal 2026 Q4 results.

https://finviz.com/quote?t=STE&p=d

First Lyme Vaccine in Decades Nears Approval

 Lyme disease remains one of the most common vector-borne infectious diseases in the Northern Hemisphere and its prevalence continues to increase. In the US, approximately 476,000 cases are diagnosed and treated each year, while Europe reported more than 130,000 annual cases.

Despite the substantial disease burden, no vaccine has been approved for human use. That may soon change.

In a press release, Pfizer and Valneva announced positive results from the phase 3 VALOR trial of their VLA15 Lyme disease vaccine.

Researchers evaluated the Lyme disease vaccine candidate PF-07307405 (LB6V, formerly VLA15) in the phase 3 VALOR trial, a randomized, placebo-controlled, blinded study conducted in endemic regions across the US, Canada, and Europe. According to ClinicalTrials.gov, the NCT05477524 trial enrolled approximately 9400 participants aged 5 years or older.

The vaccination schedule included four doses: a primary series administered at months 0, 2, and 5-9, followed by a booster dose 1 year later, given immediately before the next tick season.

The results showed clinically encouraging protection. During the second tick season after completion of the primary immunization series, the incidence of confirmed Lyme disease cases was significantly lower in the vaccine group than in the placebo group. Vaccine efficacy reached 73.2% from day 28 after the fourth dose (95% CI, 15.8%-93.5%).

Researchers have noted that fewer Lyme disease cases occurred during the trial than initially expected. A predefined primary statistical endpoint was not formally met in the first analysis. However, this criterion was achieved in a second prespecified analysis. Despite these methodological limitations, researchers have described the findings as clinically relevant.

Safety Profile

The vaccine candidate showed favorable tolerability in the VALOR study, and no safety signals were found at the time of analysis. Efficacy and safety data will guide the next steps. Based on the available findings, manufacturers plan to submit marketing authorization applications to regulatory agencies. If approved, this vaccine could become the first Lyme disease vaccine available for human use.

Mechanism of Action

The vaccine targets the outer surface protein A (OspA) of Borrelia burgdorferi. This vaccine covers six different serotypes that are epidemiologically relevant across North America and Europe.

After immunization, the body produces antibodies against OspA. When a tick feeds on the blood, these antibodies enter the tick’s gut and bind to Borrelia bacteria, blocking transmission to the human host. This vector-targeted approach differs from traditional vaccines, which primarily stimulate immune responses within the human body.

A Lyme disease vaccine, LYMErix, was approved in the US in the late 1990s. Although it showed good efficacy, it was withdrawn from the market in 2002 because of low demand, safety concerns despite limited supporting evidence, and negative public perception.

The clinical importance of an effective vaccine reflects the often nonspecific and variable presentation of Lyme disease. Early signs, such as erythema migrans or nonspecific general symptoms, are often overlooked or misinterpreted. Untreated infection can spread systemically and lead to complications, including Lyme arthritis, cardiac involvement, and neurologic manifestations. An effective vaccine could shift the focus from delayed diagnosis and treatment toward prevention. Such a change could substantially reduce the disease burden and long-term morbidity.

Vaccination may be particularly important for individuals with greater exposure to ticks, including outdoor workers and travelers to endemic regions. Researchers also expect a decline in chronic disease burden over time.

The VALOR trial findings provide robust evidence supporting the efficacy and safety of this new candidate vaccine for Lyme disease. Despite methodological limitations due to the small number of cases, the data suggest significant preventive potential.

If approved, the vaccine could reshape prevention strategies for one of the most common infectious diseases in Europe and North America, with important implications for clinical practice.

https://www.medscape.com/viewarticle/first-lyme-vaccine-decades-nears-approval-2026a1000f7r